Global Licensing Agreement Case study: ProThera Biologics and Takeda to Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins (IAIP)
Posted on24 Apr 2020
Comments0
ProThera Biologics, Inc. and Takeda Pharmaceutical Company Limited have entered into a global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor... Read More
Glenmark Foundation rolls out tele-health solution to expand access to quality patient care
Glenmark Foundation, the CSR arm of Glenmark Pharmaceuticals along with its NGO partners, has launched a tele-health solution in partnership with its... Read More
Florio GmbH introducing new digital platform aiming to improve the lives of people with haemophilia
Swedish Orphan Biovitrum AB (publ) (Sobi) has announced the launch by its affiliate, Florio GmbH, of Florio, a digital medical device designed... Read More
Gilead Sciences, Second Genome ink collaboration strategic deal in biomarker and inflammatory bowel disease drug discovery
Gilead Sciences, Inc and Second Genome, a leader in microbiome science, announced that the companies have entered into a four-year strategic collaboration... Read More
Who determines when a prescription medicine should be switched to OTC status?
Posted on07 Apr 2020
Comments0
Technically, anyone could submit a Citizen’s Petition to FDA to switch a product from Rx to OTC status. However, the holder of... Read More
What is the difference between purity and potency?
Purity means relative freedom from extraneous matter in the finished product, whether or not harmful to the recipient or deleterious to the... Read More
Case Study: US FDA approves erythroid maturation agent, Reblozyl
Bristol Myers Squibb and Acceleron Pharma Inc, a biopharmaceutical company, announced the US Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt),... Read More
Case Study: Compassionate use of remdesivir of Gilead for COVID-19
Posted on06 Apr 2020
Comments0
During an extraordinary virtual meeting held on April 2, 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral... Read More
Licensing Deal Case Study: Eisai, Seikagaku co-develop & market osteoarthritis drug, SI-613 in China
Eisai Co Ltd and Seikagaku Corporation, an R&D-oriented pharmaceutical company, announced that the companies have entered into an agreement for the co-development... Read More
Medical Devices Regulation Update – India : All medical devices will be treated as drugs from 1st of April, 2020. Learn the implication.
Posted on03 Apr 2020
TagsDPCO, medical device company, NPPA, price regulation in india, Price regulation of medical devices
Comments0
The central government on Tuesday notified all medical devices sold in the country will be treated as drugs under the Drugs and... Read More